- category:Pipeline
Pipeline
FDA accepts Eluminex's IND for DME trispecific fusion antibody
Protein therapeutic is formulated for intravitreal injection and targets key angiogenesis pathways: VEGF-A, VEGF-B, placental growth factor, Ang-2, and IL-6R.
Pipeline
Qlaris Bio raises $24M in financing for IOP-lowering glaucoma candidate
Latest funding supports ongoing clinical development of IOP-lowering therapeutic formulated to reduce episcleral venous pressure.
Pipeline
Naegis Pharma secures financing to advance retinal disease candidate
Funding will support IND-application for phase 2 trial on investigational asset, which is designed to protect the retina and cornea from damage via oral administration.
Pipeline
RevOpsis raises $16.5M to advance nAMD tri-specific therapy
Seed funding will support IND-enabling clinical studies on the first monotherapy agent to target all three angiogenic pathways.
Pipeline
SalioGen Therapeutics's gene coding therapy targets Stargardt disease
One-time, non-viral subretinal injection uses novel Gene Coding technology for gene integration.
Pipeline
Ocuphire enrolls first patient in LYNX-2 phase 3 study for phentolamine
Trial is evaluating phentolamine ophthalmic solution 0.75% (PS) for decreased VA under low (mesopic) light conditions after keratorefractive surgery.
Pipeline
Pantheon Vision closes on $1.8M to advance bioengineered corneal implants
Company’s total funding adds up to over $4 million as it seeks to eliminate corneal blindness by reducing the global reliance on donated corneal tissues.
Pipeline
Kiora Pharma secures IRD grant for late-stage RP trial
Funding from the Choroideremia Research Foundation will support testing validation in the ABACUS-2 phase 2 trial on KIO-301, a molecular photoswitch.
Pipeline
Oculis releases positive phase 3 data from OPTIMIZE-1 trial for post-op inflammation and pain
Announced at ASCRS, favorable results on once-daily, topical, and preservative-free topical formulation may support an eventual NDA submission.
Pipeline
LENZ Therapeutics reports positive phase 3 data for presbyopia eye drops
CLARITY 1 and 2 trials report statistically significant topline data for single-use, once-daily, and preservative-free LNZ100.
Pipeline
Ocugen's IND amendment gets FDA OK for phase 3 RP gene therapy trial
Investigational candidate OCU400 is the first potential treatment for RP associated with rhodopsin mutations.
Pipeline
Travoprost implant shows robust IOP-lowering in phase 3 study
Phase 3 trial finds travoprost implant as safe and effective alternative to topical IOP-lowering meds.
Pipeline
Aurion doses first Canadian patient in allogeneic cell therapy trial for CED
Corneal endothelial dysfunction candidate is being studied across clinical sites in North America.
Pipeline
Aldeyra to resubmit NDA for reproxalap DED treatment
Company plans to initiate a dry eye chamber trial four months after the FDA voiced concerns over the candidate’s clinical efficacy.
Pipeline
Nicox reports favorable IOP lowering for OAG in phase 3 eye drop trial
Latest data from Mont Blanc study finds the NO-bimatoprost combo formulation surpasses latanoprost at all time points.
Pipeline
REGENXBIO shares 2-year data on gene therapy injection for wet AMD
Dose-escalation study reports stable or improved vision and retinal anatomy up to 2 years.
Pipeline
Nanoscope reports positive data from RESTORE trial on optogenetic therapy for RP
Statistical significance noted for MCO-010 in demonstrating clinically meaningful vision improvement for legally blind, advanced RP patients.
Pipeline
Innovent Biologics' wet AMD anti-VEGF meets phase 2 primary endpoint
Intravitreal injection of high-dose IBI302 demonstrates positive long-interval dosing efficacy and safety data.
Pipeline
GenSight Biologics reports 4-year efficacy and safety data on LUMEVOQ for LHON
Latest results confirm 3-year safety and efficacy of one-time injection in unilateral- and bilateral-treated eyes.
Pipeline